CONVERSION THERAPY

Clinical trials for CONVERSION THERAPY explained in plain language.

Never miss a new study

Get alerted when new CONVERSION THERAPY trials appear

Sign up with your email to follow new studies for CONVERSION THERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 2

New combo therapy aims to shrink liver tumors enough for surgery

Disease control Recruiting now

This phase II trial tests a combination of four treatments—two immunotherapies (ipilimumab N01 and sintilimab), a targeted therapy (bevacizumab biosimilar), and chemotherapy directly into the liver—for people with advanced liver cancer that cannot be surgically removed. The goal …

Matched conditions: CONVERSION THERAPY

Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control

Last updated Jun 27, 2026 12:28 UTC

CONVERSION THERAPY

Get alerted when new CONVERSION THERAPY trials appear

New combo therapy aims to shrink liver tumors enough for surgery